[ JUDGEMENT, NOT GENERATION ]
Less information.
Better thinking.
Every other AI generates more to read. Marshy reads your team's reasoning back and shows where it breaks, before the decision ships.
- Never trains on your data
- GDPR compliant
- Judgement stays with you
We're doing IP diligence on a biologic in-licensing deal. The target's patent estate is the main attraction, broad claims lock up the whole class, nobody else gets in. Deal's priced off that exclusivity to the mid-2030s.
- HIGH
You've adopted the seller's framing: Under Amgen, breadth is not strength, it's exposure, because the broader the functional genus the harder the enablement burden.
- WATCH
Issued-and-tested is not issued-and-untested: A genus claim that has survived a PTAB challenge is worth paying for; one that hasn't is a lottery ticket priced as a bond.
- HIGH
The durable asset is the afterthought: The composition-of-matter claim is the value floor and the genus claim is the option premium, and they're priced backwards.
- Four outputs on request
- Under a minute each
- No documents required
- Export the whole session
How it works
Bring a decision
The call you are weighing up, in your own words.
Work it through
Marshy pushes back as you go. It does not write your analysis for you.
Ask for what you need
Gaps, the questions coming at you, next steps, a timeline.
A typical session
- You bring one live decision
- Marshy pressure-tests the reasoning as you talk
- You request outputs when you want them, not all at once
- Nothing is uploaded and nothing leaves your building
What you leave with
- Named gaps before they become expensive
- The questions your partners and clients will put to you
- A timeline built only on dates you have verified
- A record of the session you can share internally
It doesn't do the work.
It makes sure the work is right.
Test the reasoning
Pressure-test the plan
Prepare for the room
Sanitised example · M&A / financial strategy
Acquiring a $40bn generics business to diversify off a patent cliff
A branded pharma weighing a mostly-cash, bridge-funded acquisition to become the biggest generics player globally, with the board already supportive. Marshy took the financial case as stated and stress-tested it the way the board's own advisors would.
$1.4bn
Synergy claim
Flagged as run-rate, not a delivery curve, and untested against cost-to-achieve
3+ yrs
Timing mismatch
Synergy capture lands years after the cliff hits branded cash flow
5 questions
The board will ask
Gross-vs-net synergy, a Teva-2017 downside scenario, post-close credit rating, and more
Your decisions stay yours. Nothing you run is trained on or shared.
See it live
Bring one live decision. See what it catches.
A working session on a real call you're weighing. No commitment.
MarshyOS is operated by MarshyOS Ltd, a UK-incorporated company. Your decisions and data remain confidential by default and are never used to train the model. First session is on us; pricing is set with you once you've seen what it catches.